Market Access
Find out everything you need to know about the latest pricing, reimbursement and market access strategies that will drive your business development.
New Medicine Service will save NHS England £500m
September 11 by Pharmaceuticals & Biotechnology EditorStudy reveals UK pharmacy scheme will provide long-term savings for National Health Service (NHS) England
Novartis triumphs in cancer treatment R&D race
September 06 by Pharma IQ NewsAs many pharma manufacturers are rushing to discover the next blockbuster cancer treatment in personalized medicine, the US FDA has approved Kymriah – the first chimeric antigen receptor T cell (CAR-...
Where’s the relief from drug pricing fury?
September 05 by Pharma IQAs pharma spend continues to climb, so does public scrutiny on drug pricing. Once again, medicine manufacturers are spurred to strike a fair solution to balance raging its R&D appetites with affordabl...
When to implement a commercial patient access programme
August 29 by Dane HartungDane Hartung, Director Marketing and Access, Fougera Pharmaceuticals shares best practices for determining if and when you should implement a new Commercial Patient Access Program.
Social media: Pharma’s golden opportunity
August 14 by Pharmaceuticals & Biotechnology EditorCustomers enjoy interacting with brands on social media when it gives them great results: special offers, the chance to win prize draws, or a swift and generous response to a complaint. But, how can t...
Top 10 of who is recruiting in pharma
July 11 by Pharma IQDespite some in the market choosing to shut down certain departments, many in the pharma industry are embarking on expansions. Ireland is expected to see a lot of growth
Top 10 reputations in pharma revealed
June 20 by Pharma IQ NewsThe Reputation Institute has revealed the top 10 most reputable pharma companies as voted by the general public. In a surprising result, AstraZeneca and GSK both failed to make the top 10.
Astrazeneca hits triple oncology breakthrough
June 13 by Chanice HenryAstrazeneca and its biologics arm, Medimmune, advance in the R&D race as three new oncology drug candidates see promising developments
Medicine Optimisation: The Next Blockbuster Treatment for Pharma?
May 09 by Pharma IQPharma IQ explores the power behind medicine optimisation and the trends emerging in the pharma and healthcare market recently.
Customising Patient Education To Improve Outcomes
April 18 by Pharmaceuticals & Biotechnology EditorPatient education is an important factor in disease self-management, and when handled properly it has been found to have a significant, positive impact on improving patient outcomes.
Global Cell Therapy Figures Warn of ‘Disastrous Consequences For Science’
April 11 by Pharma IQThe International Society of Cellular Therapy (ISCT) has decided to speak out regarding oncoming health budget cuts in the US due to fears of the consequences for science, clinical care and patients i...
Russia’s Pharmaceutical Market To Double as New GDP Regulations Enforced
March 27 by Pharma IQ NewsRussia’s medicinal industry has been labelled as one of the globe’s fastest growing pharmaceutical markets and is set to rise to $38.56 billion by 2021.